Literature DB >> 24239616

Molecular and structural basis of androgen receptor responses to dihydrotestosterone, medroxyprogesterone acetate and Δ(4)-tibolone.

Tina Bianco-Miotto1, Andrew P Trotta2, Eleanor F Need3, Alice M C Lee1, Aleksandra M Ochnik1, Lauren Giorgio3, Damien A Leach3, Erin E Swinstead3, Melissa A O'Loughlin3, Michelle R Newman1, Stephen N Birrell4, Lisa M Butler1, Jonathan M Harris5, Grant Buchanan6.   

Abstract

Medroxyprogesterone acetate (MPA) has widely been used in hormone replacement therapy (HRT), and is associated with an increased risk of breast cancer, possibly due to disruption of androgen receptor (AR) signaling. In contrast, the synthetic HRT Tibolone does not increase breast density, and is rapidly metabolized to estrogenic 3α-OH-tibolone and 3β-OH-tibolone, and a delta-4 isomer (Δ(4)-TIB) that has both androgenic and progestagenic properties. Here, we show that 5α-dihydrotestosterone (DHT) and Δ(4)-TIB, but not MPA, stabilize AR protein levels, initiate specific AR intramolecular interactions critical for AR transcriptional regulation, and increase proliferation of AR positive MDA-MB-453 breast cancer cells. Structural modeling and molecular dynamic simulation indicate that Δ(4)-TIB induces a more stable AR structure than does DHT, and MPA a less stable one. Microarray expression analyses confirms that the molecular actions of Δ(4)-TIB more closely resembles DHT in breast cancer cells than either ligand does to MPA.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Androgen receptor; Coactivators; Medroxyprogesterone acetate; Molecular models; Progestins; Testosterone

Mesh:

Substances:

Year:  2013        PMID: 24239616     DOI: 10.1016/j.mce.2013.11.002

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  1 in total

1.  Colorectal tumor prevention by the progestin medroxyprogesterone acetate is critically dependent on postmenopausal status.

Authors:  Bartolomeus J Meijer; Mattheus C B Wielenga; Patricia B Hoyer; James M Amos-Landgraf; Theodorus B M Hakvoort; Vanesa Muncan; Jarom Heijmans; Gijs R van den Brink
Journal:  Oncotarget       Date:  2018-07-17
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.